The Zhitong Finance App learned that CICC released a research report stating that considering fluctuations in health care product performance and the company's medical AI investment pace, Alibaba Health (00241.HK) 2027FY and 2028FY non-GAAP net profit forecasts were lowered by 6.6%/5.8% to 2,178 billion yuan and 2,421 billion yuan. Considering recent valuation fluctuations in the Hong Kong stock Internet healthcare sector, and that the 2Q27FY period policy also brought some emotional suppression to the regulation of the health products industry, the bank lowered the company's target price by 30.8% to HK$4.5 based on SOTP, which has 54% room to rise compared to the current stock price, maintaining a “outperforming the industry” rating. The bank expects the company's 1H27FY revenue to achieve a high single-digit year-on-year growth rate, and non-GAAP net profit may remain basically flat.

The Zhitong Finance App learned that CICC released a research report stating that considering fluctuations in health care product performance and the company's medical AI investment pace, Alibaba Health (00241.HK) 2027FY and 2028FY non-GAAP net profit forecasts were lowered by 6.6%/5.8% to 2,178 billion yuan and 2,421 billion yuan. Considering recent valuation fluctuations in the Hong Kong stock Internet healthcare sector, and that the 2Q27FY period policy also brought some emotional suppression to the regulation of the health products industry, the bank lowered the company's target price by 30.8% to HK$4.5 based on SOTP, which has 54% room to rise compared to the current stock price, maintaining a “outperforming the industry” rating. The bank expects the company's 1H27FY revenue to achieve a high single-digit year-on-year growth rate, and non-GAAP net profit may remain basically flat.